Research Article
A Comparison of Epitope Repertoires Associated with Myasthenia Gravis in Humans and Nonhuman Hosts
Table 7
Epitopes associated with immunomodulation.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Data were derived by querying the database for EAMG. Positive T-cell and B cell assay data were downloaded using Excel format. For Myasthenogenic peptides the worksheet was filtered for “Administration in vivo to cause disease” in the following columns: “1st In Vivo Process Type” or “2nd In Vivo Process Type” or “Adoptive Transfer In Vivo Process Type,” one at a time. For tolerogenic or therapeutic peptides the worksheet was filtered for “Administration in vivo to prevent or reduce disease” in the in the same columns. *Asterisk indicates that the peptide was shown to both induced disease and to reduce disease depending upon the sequence given.**This peptide was synthesized with a norleucine substitution at M20. ***Disease enhancement was associated with adoptive transfer of epitope-specific T-cells; pretreatment induced tolerance. It is also possible to search by assay type: treatment assay, tolerance induction, and exacerbation. Typing the exact sequence into the linear peptide field on the Home Page Search Interface will generate results summary table for the investigation of individual records. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||